About John Mulligan
John Mulligan is a chief executive officer and director at Bonum Therapeutics.
John Mulligan first appears on SEC filings in 2021.
Experience
This experience comes from John Mulligan's profile and from SEC filings. For roles taken from filings, the years are when the filings name John Mulligan in the role, so the role may have started earlier or lasted longer.
NI
Nagoon Therapeutics, Inc. Current
Co-Founder
2022 – Present
Bonum Therapeutics, Inc. Current
Founder and CEO (2022 – Present)
Director
2021 – Present · Seattle, WA
Develops targeted protein medicines for people with cancer.
GI
Good Therapeutics, Inc.
Founder and CEO
2016 – 2022
MI
Microsoft
Consultant
2015 – 2020
PI
Pacific Northwest Diabetes Research Institute
Scientist
2013 – 2015
GI
Glycostasis, Inc.
Founder and CEO
2012 – 2015
CG
Cambrian Genomics
Molecular Biology Guru
2012 – 2015
AL
Auxin Partners, LLC
Associate Partner
2011 – 2012
BL
Blue Heron Biotech LLC
Founder, President and CEO, and then CSO
1999 – 2010
DM
Darwin Molecular
Director of Genomics
1994 – 1998
SM
Stanford University School of Medicine
Research Assistant Professor (1991 – 1994)
Postdoctoral Fellow (1988 – 1991)
1988 – 1994
Key Colleagues at Startups
The people John Mulligan works with at each company, as listed on that company's latest Form D.
Bonum Therapeutics, Inc. · Form D, Apr 17, 2026
Samuel Bjork
Executive Chair
Monique Schiersing
Senior Investment Director, Roche Venture
Neela Patel
Chief Business Officer
JM
John McKearn
Director
Diane Hollenbaugh
Chief Scientific Officer
Samuel Blackman
Independent Director
Karl Handelsman
Founder & Managing Partner, Codon Capital, director
NW
Nicholas Walrod
Director
MM
Mitchell Mutz
Independent Director
Gaurav Aggarwal
Managing Partner, Vivo Capital and director